No Data
No Data
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table
H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright analyst Andrew Fein maintains $Kymera Therapeutics(KYMR.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 49.4
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Piper Sandler analyst Edward Tenthoff maintains $Kymera Therapeutics(KYMR.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 0.
Kymera Therapeutics(KYMR.US) Director Sells US$950.17K in Common Stock
$Kymera Therapeutics(KYMR.US)$ Director Booth Bruce sold 26,940 shares of common stock on Jun 12, 13, 2024 at an average price of $35.27 for a total value of $950.17K.Source: Announcement What is stat
Express News | Kymera Therapeutics Shares New Clinical Data From Its Ongoing KT-333 Phase 1 Trial; Data Were Presented At European Hematology Association (EHA) Annual Meeting
Express News | Kymera Therapeutics Inc: KT-333 Was Well-Tolerated With Phase 1 Dose Escalation Ongoing and Additional Data Expected in Second Half of 2024